Feasibility study of carboplatin plus TS-1 combination chemotherapy for completely resected non-small cell lung cancer (ALCSG-1001)

Feasibility study of carboplatin plus TS-1 combination chemotherapy for completely resected non-small cell lung cancer (ALCSG-1001) - Feasibility study of carboplatin plus TS-1 combination chemotherapy for completely resected non-small cell lung cancer (ALCSG-1001)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003993

Enrollment

Registered

2010-08-04

Start date

2010-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

completely resected non-small cell lung cancer

Interventions

carboplatin plus TS-1 combination chemotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Pathological stage II/IIIA non-small cell lung cancer. 2. Completely resected non-small cell lung cancer. 3. No prior treatment. 4. Aged 20 to 74 years old. 5. Performance status of 0 or 1. 6. Sufficient organ functions. 7. Written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients unable to get treatment of CBDCA or TS-1. 2. Sever allergy. 3. Interstitial pneumonia. 4. Active concomitant neoplasia. 5. uncontrolled heart diseases. 6. Pregnant, lactating women. 7. Sever complications. 8. Inappropriate patients judged by physicians.

Design outcomes

Primary

Measure	Time frame
Rate of treatment accomplishment	—

Secondary

Measure	Time frame
Safety, overall survival, relapse-free survival	—

Countries

Japan

Contacts

Public ContactYoshinobu Ohsaki

Asahikawa Medical University Hospital Respiratory Center

yohsaki@asahikawa-med.ac.jp+81-166-69-3290

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026